About Us

About Us

Zonsen PepLib Biotech Inc.


湖南中晟全肽生化有限公司

Zonsen PepLib Biotech Inc. is a high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with a subsidiary in New Jersey, USA.

 

Our core peptide discovery platform is called Peptide Information Compression Technology (PICT), which consists of a diverse peptide library named ZSenithFive®, containing information on nearly half-billion peptides. The PICT platform is ideal for the discovery of functionally active peptides directly from cell-based and biochemical high-throughput screening (HTS) assays. In addition, we have developed 4 complimentary peptide discovery platforms: the Disulfide-rich Peptide Phage Display (DRP-PD) platform, the Animal Toxin Peptide Library Platform, the Nano-Cyclic Peptide Library Platform, and the Virtual Peptide Library Platform.

 

PepLib successfully raised 100 million yuan (USD 16 million) in Series Pre-A financing in 2019 and secured Series A financing of 220 million yuan (USD 35 million) in 2021. PepLib has been working towards Series Pre-IPO financing since August 2023. PepLib has more than 190 employees, and more than 80% of the workforce is made up of R&D personnel.

 

At PepLib, our main therapeutic area focus is oncology and cardiometabolic diseases. where oncology programs are driven by the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs).

R&D Input

Accumulated R&D input of approximately 380 million yuan, with 600 million yuan expected to be invested in the next 3 years.

New Drug Milestone Service + Self-developed Pipelines.
.

R & D investment

Company Appearance

Staff Environment Equipment
STAFF
STAFF
STAFF
STAFF
Company location
Company location
FLIPR tetra

FLIPR tetra

Biotek Cytation10

Biotek Cytation10

Biotek Cytation5

Biotek Cytation5

Biotek Synergy neo2

Biotek Synergy neo2

LOGO